This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (63)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Articles for Residents  • Macular Degeneration  • Alert me on articles by topic

Jost B. Jonas, MD; Imren Akkoyun, MD; Wido M. Budde, MD; Ingrid Kreissig, MD; Robert F. Degenring, MD

Arch Ophthalmol. 2004;122:218-222.

Objective  To evaluate the outcome of repeated intravitreal injections of triamcinolone acetonide for the treatment of exudative age-related macular degeneration.

Methods  This prospective, comparative nonrandomized clinical interventional study included 13 patients with progressive exudative age-related macular degeneration with occult, or predominantly occult, subfoveal neovascularization. All patients had shown an increase or stabilization of visual acuity after a first intravitreal injection of 25 mg of triamcinolone acetonide. They received a second intravitreal injection of 25 mg of triamcinolone acetonide 3.1 to 18 months after the first injection. Mean ± SD follow-up time after the second injection was 5.2 ± 3.6 months (median, 5.3 months). A control group included 24 patients with exudative age-related macular degeneration who did not receive treatment for their maculopathy. The main outcome measures were visual acuity and intraocular pressure.

Results  In the study group, mean ± SD visual acuity increased significantly (P = .005 and P = .003, respectively) from 0.17 ± 0.11 to 0.32 ± 0.26 and from 0.15 ± 0.14 to 0.23 ± 0.19, respectively, after the first and second injections. An increase in visual acuity was found for 10 patients (77%) after the first and second injections. In the control group, visual acuity did not vary significantly during follow-up (P = .81). The difference in change in visual acuity between the study group and control group was significant (P = .01 [Snellen lines] and P = .05 [logMAR units]). The peak in visual acuity and, in a chronologically parallel manner, the peak in intraocular pressure elevation occurred 2 to 5 months after each injection.

Conclusions  Repeated intravitreal injection of 25 mg of triamcinolone acetonide may lead to an increase in visual acuity in patients with exudative age-related macular degeneration, with the peak in visual acuity and intraocular pressure elevation occurring about 2 to 5 months after each injection.

From the Department of Ophthalmology, Faculty of Clinical Medicine of Mannheim, University of Heidelberg, Heidelberg, Germany. The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections
Tammewar et al.
Br. J. Ophthalmol. 2008;92:810-813.
ABSTRACT | FULL TEXT  

Short-term Safety and Efficacy of Intravitreal Triamcinolone Acetonide for Uveitic Macular Edema in Children
Sallam et al.
Arch Ophthalmol 2008;126:200-205.
ABSTRACT | FULL TEXT  

Triamcinolone Acetonide-Mediated Oxidative Injury in Retinal Cell Culture: Comparison with Dexamethasone
Chung et al.
IOVS 2007;48:5742-5749.
ABSTRACT | FULL TEXT  

Triamcinolone Acetonide Inhibits IL-6- and VEGF-Induced Angiogenesis Downstream of the IL-6 and VEGF Receptors
Ebrahem et al.
IOVS 2006;47:4935-4941.
ABSTRACT | FULL TEXT  

Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema
Chan et al.
Br. J. Ophthalmol. 2006;90:1137-1141.
ABSTRACT | FULL TEXT  

The problem of pressure elevation associated with intravitreal triamcinolone.
Conway
Br. J. Ophthalmol. 2006;90:934-935.
FULL TEXT  

Intraocular pressure alterations following intravitreal triamcinolone acetonide
Rhee et al.
Br. J. Ophthalmol. 2006;90:999-1003.
ABSTRACT | FULL TEXT  

Should corticosteroids be considered as part of the standard care with photodynamic therapy?
Zarbin
Arch Ophthalmol 2006;124:563-571.
FULL TEXT  

Electroretinographic Effects of an Intravitreal Injection of Triamcinolone in Rabbit Retina
Dierks et al.
Arch Ophthalmol 2005;123:1563-1569.
ABSTRACT | FULL TEXT  

Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2005;123:1338-1343.
ABSTRACT | FULL TEXT  

Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use
Garcia-Arumi et al.
Br. J. Ophthalmol. 2005;89:1112-1114.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor Reduced and Connective Tissue Growth Factor Induced by Triamcinolone in ARPE19 Cells under Oxidative Stress
Matsuda et al.
IOVS 2005;46:1062-1068.
ABSTRACT | FULL TEXT  

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study
Jonas et al.
Br. J. Ophthalmol. 2005;89:321-326.
ABSTRACT | FULL TEXT  

Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema
Jonas et al.
Br. J. Ophthalmol. 2005;89:122-122.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Macular Edema--Reply
Jonas et al.
Arch Ophthalmol 2004;122:1086-1088.
FULL TEXT